Cercar
01/12/2025
Peripheral Nerve Society Training Grant Program: An Exciting Opportunity Not to Be Missed
Alberti, P, Querol, L. Peripheral Nerve Society Training Grant Program: An Exciting Opportunity Not to Be Missed. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(4)DOI:10.1111/jns.70076. PMID:41236205. IF:3.200(Q2/4D).
01/12/2025
Insight in the Unmet Needs Encountered During the Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Allen, JA, Lehmann, HC, Nobile-Orazio, E, Querol, L, Rajabally, YA. Insight in the Unmet Needs Encountered During the Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(4)DOI:10.1111/jns.70067. PMID:41054275. IF:3.200(Q2/4D).
01/10/2025
ADHERE plus trial interim analysis: long-term safety and efficacy of efgartigimod in chronic inflammatory demyelinating polyneuropathy (CIDP)
Eggers, C, Allen, J, Lin, J, Stettner, M, Guptill, J, Istas, G, De Roeck, A, Kuwabara, S, Lauria, G, Querol, L, Suresh, N, Karam, C, Skripuletz, T, Rinaldi, S, Echaniz-Laguna, A, Hewamadduma, C, Van Hoorick, B, Yamasaki, R, van Doorn, P, Lewis, R. ADHERE plus trial interim analysis: long-term safety and efficacy of efgartigimod in chronic inflammatory demyelinating polyneuropathy (CIDP). NEUROMUSCULAR DISORDERS. 2025; 53DOI:10.1016/j.nmd.2025.105858. PMID:. IF:2.800(Q2/5D).
01/10/2025
208-week efficacy and safety of cipaglucosidase alfa plus miglustat in patients with late-onset Pompe disease treated from PROPEL baseline: muscle function and biomarkers
Toscano, A, Bratkovic, D, Claeys, K, Díaz-Manera, J, Mozaffar, T, Roberts, M, Schoser, B, van der Ploeg, A, Jain, V, Holdbrook, F, Moore, P, O'Brien-Prince, K, Kishnani, P. 208-week efficacy and safety of cipaglucosidase alfa plus miglustat in patients with late-onset Pompe disease treated from PROPEL baseline: muscle function and biomarkers. NEUROMUSCULAR DISORDERS. 2025; 53DOI:10.1016/j.nmd.2025.105857. PMID:. IF:2.800(Q2/5D).
01/10/2025
Brachio-cervical inflammatory myopathy: evidence for a distinct form of inflammatory muscle disease
Kleefeld, F, Vigo, EG, Gamboa, JT, Funke, A, Roos, A, Mensch, A, Gehrig, J, Ruck, T, Mossakowski, A, Llanso, L, Bortolani, S, Torchia, E, Casal-Dominguez, M, Pinal-Fernandez, I, Mammen, A, Tasca, G, Preusse, C, Stenzel, W. Brachio-cervical inflammatory myopathy: evidence for a distinct form of inflammatory muscle disease. NEUROMUSCULAR DISORDERS. 2025; 53DOI:10.1016/j.nmd.2025.105458. PMID:. IF:2.800(Q2/5D).
01/09/2025
Monitoring Patients with Relapsing-Remitting Multiple Sclerosis Switching from Intravenous to Subcutaneous Natalizumab every 4 Weeks vs every 6 Weeks
Moreno, AA, Presas-Rodríguez, S, Gonzalez-Garcia, AM, Teniente-Sera, A, Martínez-Cáceres, EM, Querol, L, Martín-Aguilar, L, Meca-Lallana, JE, Dos Santos, CE, Millán, J, López, GV, Orgaz, ATC, Ruiz, VC, Anunciación, BAJ, Hervas, JV, Ruiz, LB, Bravo, GCA, Ramo, C. Monitoring Patients with Relapsing-Remitting Multiple Sclerosis Switching from Intravenous to Subcutaneous Natalizumab every 4 Weeks vs every 6 Weeks. Multiple Sclerosis Journal. 2025; 31(3)DOI:. PMID:. IF:5.000(Q1/2D).
01/09/2025
Cracking the code: genotype-phenotype correlation models in sarcoglycanopathies
Luce, L, Kocak, G, Alonso-Pérez, J, Straub,, Töpf, A, Díaz-Manera, J. Cracking the code: genotype-phenotype correlation models in sarcoglycanopathies. NEUROMUSCULAR DISORDERS. 2025; 53DOI:. PMID:. IF:2.800(Q2/5D).
01/09/2025
Denervated human muscle fibers promote reinnervation via neurotrophic factor release in SMA and ALS
Gokul-Nath, R, Collins, C, Valverde, L, Lleixa, C, Verdu-Diaz, J, Di Lorenzo, A, Llarch, P, Querol, L, Marini-Bettolo, C, Rojas-Garcia, R, Diaz-Manera, J. Denervated human muscle fibers promote reinnervation via neurotrophic factor release in SMA and ALS. NEUROMUSCULAR DISORDERS. 2025; 53DOI:10.1016/j.nmd.2025.105462. PMID:. IF:2.800(Q2/5D).